The Sage Group advised Zhimeng Biopharma on a worldwide license to GSK of CB06-036, a TLR8 Agonist
In December 2022, GSK entered into an exclusive license agreement with biopharma company Zhimeng for CB06-036, a TLR8 agonist. Subject to successful completion of phase I, the agreement will allow GSK to develop, manufacture and commercialise CB06-036. If successful, CB06-036 could be used in combination, or as a sequential treatment with bepirovirsen, to potentially achieve functional cure in more patients.
The Sage Group advised Zhimeng Biopharma on this transaction.